Angiosarcoma Clinical Trial
Official title:
Single-arm, Multicenter, Open Label Phase II Trial to Evaluate the Efficacy of Pazopanib in Combination With Paclitaxel in Advanced and Relapsed Angiosarcoma
Open-label phase II trial investigating the efficacy and safety of the investigational combination of pazopanib and paclitaxel.
Open-label phase II trial investigating the efficacy and safety of the investigational combination of pazopanib and paclitaxel.This multi-center, open-label, prospective, single arm phase II study was designed to evaluate the clinical efficacy and safety of the experimental combination of pazopanib with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.The safety evaluations (physical examination, laboratory checks as defined in protocol, toxicity/adverse event assessment according Eastern Cooperative Oncology Group version 4.0) are scheduled every cycle at day 1, 8, 15 and 29 (= day 1 of the next cycle). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
Completed |
NCT01303497 -
Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas
|
Phase 2 | |
Recruiting |
NCT02625389 -
Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization.
|
Phase 4 | |
Completed |
NCT04293289 -
Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma
|
N/A | |
Recruiting |
NCT05859074 -
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
|
Phase 1 | |
Not yet recruiting |
NCT02732678 -
Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04055220 -
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
|
N/A | |
Recruiting |
NCT06375941 -
Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars
|
||
Recruiting |
NCT05799612 -
Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma
|
Phase 1 | |
Withdrawn |
NCT05116800 -
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
|
Phase 2 | |
Recruiting |
NCT01042379 -
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01786889 -
Identification, Molecular Epidemiology Angiosarcoma of the Liver France
|
N/A | |
Active, not recruiting |
NCT02834013 -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03331250 -
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
|
Phase 2 | |
Completed |
NCT02584309 -
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
Not yet recruiting |
NCT06277154 -
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Withdrawn |
NCT04607200 -
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
|
Phase 2 | |
Completed |
NCT04518124 -
Propranolol in Angiosarcoma
|
Phase 2 | |
Recruiting |
NCT05961761 -
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
|
Phase 2 | |
Completed |
NCT00887809 -
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
|
Phase 2 |